Jiangsu Bio-Sincere Pharmaceutical Technology Co., Ltd. is an innovative pharmaceutical company driven by drug research and development to propel the entire pharmaceutical industry chain. It primarily focuses on the research and development of 505(b)(2) category improved new drugs and high-end specialized generic drugs. The company possesses advanced technology platforms, including a novel nanomicellar drug delivery system and an artificial intelligence and transcriptome big data platform. It provides domestic and international clients with technology transfer and contract research and development services for new drugs and generic drugs, comprehensively building the company's core competitiveness.

Strong R&D Capabilities

Rich Industrial Resource Advantages: The core team has nearly two decades of deep experience in the biopharmaceutical industry, possessing substantial industrial resources and top-tier project establishment, research, and development experience and capabilities in China.

Exclusive Technology Platform Advantages: The big data platform and micellar platform are exclusively owned by Bio-Sincere, enabling rapid, low-cost, and systematic development of new uses for existing drugs.

Differentiated Layout Strategy

Based on the Marketing Authorization Holder (MAH) system, the company combines Contract Manufacturing Organization (CMO) and Contract Sales Organization (CSO) approaches to develop and market self-owned improved new drugs and generic drugs, while also providing drug contract research and development services externally. With 505(b)(2) improved new drugs as the flagship and high-end specialized generic drugs as supplements, the company ensures strong certainty for product market entry.